Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
on page 1 showing 20 out of 31 results from 1 sources

    ACCORD

Cite this (ACCORD, RRID:SCR_009015)

URL: https://www.accordtrial.org/public

Resource Type: Resource, clinical trial

Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study.

  • From Current Category

    BARI 2D

Cite this (BARI 2D, RRID:SCR_001496)

URL: http://www.bari2d.org/

Resource Type: Resource, clinical trial

A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes??????insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ?????? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care.

  • From Current Category

Cite this (Cardiovascular Model Repository, RRID:SCR_002679)

URL: https://simtk.org/home/cv-gmodels

Resource Type: Resource, image collection, data set, service resource, storage service resource, data repository, data or information resource

Repository of geometric models collected from on-going and past research projects in the Cardiovascular Biomechanics Research Laboratory at Stanford University. The geometric models are mostly built from imaging data of healthy and diseased individuals. For each of the models, a short description is given with a reference. The geometric models are in VTK PolyData XML .vtp format. * Audience: Biomechanical and computational researchers interested in complex models of cardiovascular applications * Long Term Goals and Related Uses: Allow users to download geometric models for cardiovascular applications. These geometric models can be used for research purposes, such as meshing and scientific visualization. Users are welcome to contact the project administrator, join the project and contribute additional models.

  • From Current Category

Cite this (Chronic Renal Insufficiency Cohort Study, RRID:SCR_009016)

URL: http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/

Resource Type: Resource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resource

Observational national cohort study poised to make fundamental insights into the epidemiology, management, and outcomes of chronic kidney disease (CKD) in adults with intended long-term follow up. The major goals of the CRIC Study are to answer two important questions: why does kidney disease get worse in some people, but not in others, and why do persons with kidney disease commonly experience heart disease and stroke?

  • From Current Category

Cite this (CKID A Prospective Cohort Study of Kidney Disease in Children, RRID:SCR_001500)

URL: http://www.statepi.jhsph.edu/ckid/

Resource Type: Resource, disease-related portal, topical portal, bibliography, research forum portal, portal, data or information resource

Prospective, observational cohort study of children with mild to moderate chronic kidney disease (CKD) to: (1) determine risk factors for progression of pediatric chronic kidney disease (CKD); (2) examine the impact of CKD on neurocognitive development; (3) examine the impact of CKD on risk factors for cardiovascular disease, and; (4) examine the impact of CKD on growth. The CKiD study population will include a cohort of 540 children, age 1 16 years, expected to be enrolled over a 24-month period.

  • From Current Category

    ClinMet

Cite this (ClinMet, RRID:SCR_003979)

URL: http://sharpentrials.com/

Resource Type: Resource, commercial organization, organization portal, portal, data or information resource

Commercial organization that uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Their combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Their efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug''s mechanism of action.

  • From Current Category

Cite this (Comprehensive Biomarker Center, RRID:SCR_003901)

URL: http://www.cbioc.com/en/

Resource Type: Resource, service resource, commercial organization

Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies.

  • From Current Category

Cite this (CryoLife, Inc., RRID:SCR_005037)

URL: http://www.cryolife.com

Resource Type: Resource, production service resource, biomaterial supply resource, tissue bank, material service resource, service resource, material resource

A biological medical device company that focuses on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular for patients of all ages. The Company''s research and development efforts are focused on Protein Hydrogel Technologies, such as BioFoam Surgical Matrix for parenchymal organ sealing. The Company is also investigating additional applications for its SynerGraft decellularization technology. CryoLife provides surgeons with multiple tissue options for cardiovascular reconstruction. CryoLife preserved allografts have helped save the lives and limbs of patients for 20 years. CryoLife''s tissue, along with BioGlue and BioFoam offer a wide range of Life Restoring Technologies for cardiac and vascular surgeons. CryoLife provides innovative products that will benefit patients around the world by working with other pioneering companies and by continuous investment in research and development.

  • From Current Category

Cite this (deCODE genetics, RRID:SCR_003334)

URL: http://www.decode.com/

Resource Type: Resource, commercial organization, organization portal, portal, data or information resource

A biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. They specialize in gene discovery - their population approach and resources have enabled them to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer. The company's genotyping capacity is now one of the highest in the world. They have a large population-based biobank containing whole blood and DNA samples with extensive relevant phenotypic information from around 120.000 Icelanders. In the company's work in more than 50 disease projects, their statistical and informatics departments have established themselves in data processing and analysis. deCODE genetics is widely recognized as a center of excellence in genetic research.

  • From Current Category

Cite this (Diabetes Prevention Program Outcomes Study, RRID:SCR_001502)

URL: http://www.bsc.gwu.edu/dpp/protocol.htmlvdoc

Resource Type: Resource, clinical trial

Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDK sample repository for DPP participants.

  • From Current Category

Cite this (Folic Acid for Vascular Outcome Reduction in Transplantation, RRID:SCR_001505)

URL: http://www.cscc.unc.edu/favorit/

Resource Type: Resource, clinical trial

Multi-center, randomized, double blind controlled clinical trial to determine whether treatment with a standard multivitamin augmented with high doses of folic acid, vitamin B6 and vitamin B12 reduces the rate of cardiovascular disease outcomes in renal transplant recipients relative to participants receiving a similar multivitamin that contains no folic acid. This study hopes to show that by reducing the level of homocysteine in the body, the risk of heart disease is also reduced among kidney transplant patients.

  • From Current Category

Cite this (Fondazione Centro San Raffaele; Milan; Italy, RRID:SCR_003894)

URL: http://www.fondazionesanraffaele.it/

Resource Type: Resource, organization portal, portal, funding resource, data or information resource

A non-profit organization to support the research of the IRCCS San Raffaele Hospital with the aim of helping the development of science in the service of medicine. To make progress and achieve new successes, which may also be of benefit to future generations, the Fondazione Centro San Raffaele Hospital supports through participation in invitations to national and international research and fundraising activities to individuals and businesses. The lines of research in 2013 which focuses on the activities of the Foundation, in synergy with the San Raffaele hospital: # Molecular and functional approaches to the study of neurological and psychiatric disorders # Molecular and cellular therapies for regenerative medicine # Study and modulation of innate and adaptive immune response # Cellular and molecular approaches to the study of solid tumors and blood # Molecular and cellular approaches to the study and treatment of cardiovascular and metabolic diseases # Genetic mechanisms, molecular and cellular disease and aging # Genomics and post-genomics for the study of the mechanisms of disease and response to drugs # Molecular and cellular imaging for the study of oncological diseases and molecular imaging of cardiovascular disease

  • From Current Category

Cite this (Framingham Heart Study, RRID:SCR_008963)

URL: http://www.framinghamheartstudy.org/

Resource Type: Resource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, data set, portal, material resource, data or information resource

A longitudinal, epidemiologic study to identify the common risk factors or characteristics that contribute to cardiovascular disease by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms or suffered a heart attack or stroke. Since that time the FHS has studied three generations of participants resulting in biological specimens and data from nearly 15,000 participants. Since 1994, two groups from minority populations, including related individuals have been added to the FHS. FHS welcomes proposals from outside investigators for data and biospecimens. The researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have continued to return to the study every two years for a detailed medical history, physical examination, and laboratory tests, and in 1971, the Study enrolled a second generation - 5,124 of the original participants'''' adult children and their spouses - to participate in similar examinations. In 1994, the need to establish a new study reflecting a more diverse community of Framingham was recognized, and the first Omni cohort of the Framingham Heart Study was enrolled. In April 2002 the Study entered a new phase, the enrollment of a third generation of participants, the grandchildren of the Original Cohort. In 2003, a second group of Omni participants was enrolled. Over the years, careful monitoring of the Framingham Study population has led to the identification of major CVD risk factors, as well as valuable information on the effects of these factors such as blood pressure, blood triglyceride and cholesterol levels, age, gender, and psychosocial issues. Risk factors for other physiological conditions such as dementia have been and continue to be investigated. In addition, the relationships between physical traits and genetic patterns are being studied. FHS clinical and research data is stored in the dbGaP and NHLBI Repository repositories and may be accessed by application. Please check the following repositories before applying for data through FHS. Investigators seeking data that is not available through dbGaP or BioLINCC or seeking biological specimens may submit a proposal through the FHS web-based research application. The FHS data repository may be accessed through this FHS website, under the For Researchers link, then Description of Data, in order to determine if and how the desired data is stored. Proposals may involve the use of existing data, the collection of new data, either directly from participants or from previously collected samples, images, or other materials (e.g., medical records). The FHS Repository also has biological specimens available for genetic and non-genetic research proposals. Specimens include urine, blood and blood products, as well as DNA.

  • From Current Category

Cite this (Geisinger Biobank, RRID:SCR_005652)

URL: http://www.geisinger.org/research/centers_departments/genomics/mycode/mycode.html

Resource Type: Resource, biomaterial supply resource, material resource, data or information resource

By collecting and analyzing blood samples from Geisinger''s large patient population, MyCode will help unlock the mysteries of some of the most devastating and debilitating diseases. Blood samples are obtained from patients of certain Geisinger specialty clinics to study specific conditions, such as obesity and cardiovascular disease, and also from patients of Geisinger primary care clinics to provide a representative sample of the regional population. More than 60,000 samples from over 23,000 Geisinger patients have been collected so far, and sample collection is ongoing. MyCode researchers use the blood samples to study the genetic causes of diseases and certain disease-related molecular mediators. Knowledge gained from these studies will allow researchers to pursue innovative approaches to disease prevention, diagnosis and treatment. To be of value for Genomic Medicine research, bio-banked samples must be connected to clinical data: MyCode allows genetic and molecular data about the samples to be connected to medical data in a way that protects patient identity. When a patient agrees to participate in MyCode, blood samples for the MyCode Project are collected during blood draws ordered as part of the patient''s routine medical care. After the sample is drawn and labeled, a staff member from the Weis Center for Research transports the blood to the Geisinger Clinic Genomics Core (GCGC) where it is processed for storage. At this stage, all personal identification markers are removed and the samples are assigned a randomly-selected identification number. A secure key is maintained that allows approved researchers to connect the samples to the clinical data for genomic studies in a way that ensures confidentiality of the information. To maintain confidentiality of MyCode data the code linking the research numbers and the electronic health records are kept in a password-protected files accessible only to MyCode team members. Additionally, all results generated from the samples are reported as a group so that individuals are not identified. The samples are stored indefinitely.

  • From Current Category

Cite this (Janssen Research and Development, RRID:SCR_003904)

URL: http://www.janssenrnd.com/

Resource Type: Resource, commercial organization, organization portal, portal, data or information resource

Pharmaceutical company with a mission to discover and develop innovative medicines that ease patients'' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, their strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. They leverage their world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology.

  • From Current Category

Cite this (KI Biobank - CEFAM, RRID:SCR_006044)

URL: http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=80149&l=en

Resource Type: Resource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resource

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. CEFAM: Risk factors for atherosclerosis and cardiovascular disease, a randomized controlled study among women from the Middle East and Latin America. The study aims to analyze how two different physical activity programs in overweight and sedentary immigrant women influence changes in biomarkers related to glucose- and lipid metabolism, stress related hormone production, sub clinical inflammation, chronic cyclooxygenase mediated inflammation and oxidative stress.

  • From Current Category

Cite this (KI Biobank - PAROKRANK, RRID:SCR_006045)

URL: http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=103574&l=en

Resource Type: Resource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resource

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. Cardiovascular disease and periodontitis are common diseases, causing considerable suffering and costs. Despite strong links between the two diseases it is unclear if periodontitis causes cardiovascular disease. The primary aims are to investigate whether periodontitis is a risk factor for the development of myocardial infarction and if periodontitis increases the risk for new cardiovascular events such as myocardial infarction, stroke and death in patients with a previous myocardial infarction. PAROKRANK is a case control study. Cases (n=1500) are patients with a first myocardial infarction and controls population derived people without cardiovascular disease(n=1500). Both groups are subjected to predefined dental examinations, analyses of a variety of risk factors and a biobank of blood and dental samples will be established. Information is collected from available registries (RIKS-HIA and SEPHIA) and study specific records.

  • From Current Category

Cite this (Mario Negri Institute for Pharmacological Research; Milan; Italy, RRID:SCR_011361)

URL: http://www.marionegri.it/mn/en/

Resource Type: Resource, institution

A not-for-profit biomedical research institute whose main aim is to help defend human health and life. Research programs span from the molecular level to the whole human being, and the findings help build up the basis for developing new drugs, and making existing ones more effective. The main research headings are the battle against cancer, nervous and mental illnesses, cardiovascular and kidney diseases, rare diseases and the toxic effects of environmental contaminants, mother and child''''s health. The Institute is also involved in research on pain relief and drug addiction. Parallel to its biomedical investigations, the Mario Negri Institute runs training schemes for laboratory technicians and graduate researchers. It takes part in a range of initiatives to communicate information in biomedicine, on a general level and with the specific aims of improving health care practice, and encouraging more rational use of drugs. There are also research units in Bergamo, at Ranica - near Bergamo - and at Santa Maria Imbaro, near Chieti.

  • From Current Category

    Merck

Cite this (Merck, RRID:SCR_001287)

URL: http://www.merck.com/

Resource Type: Resource, reagent supplier, material resource, antibody supplier

An American pharmaceutical company aiming to make a difference in the lives of people globally through their medicines, vaccines, biologic therapies and animal health products.

  • From Current Category

Cite this (National Genome Research Network, RRID:SCR_006626)

URL: http://www.ngfn.de/en/start.html

Resource Type: Resource, organization portal, portal, data or information resource

The program of medical genome research is a large-scale biomedical research project which extends the national genome research net (NGFN) and will be funded by the federal ministry of education and research (BMBF) from 2008-2013. Currently the program includes two fields: * Research ** NGFN-Plus: With the aim on combating diseases that are central to health policy, several hundred researchers are systematically investigating the complex molecular interactions of the human body. They are organized in 26 Integrated Genome Research Networks. * Application ** NGFN-Transfer: The rapid transfer of results from medical genome research into medical and industrial application is the aim of the scientists from research institutes and biomedical enterprises that cooperate in eight Innovation Alliances. AREAS OF DISEASE * Cardiovascular disease * Cancer * Neuronal diseases * Infections and Inflammations * Environmental factors

  • From Current Category

  1. Resource Identification Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Save Your Search

    You can save any searches you perform for quick access to later from here.

  6. Query Expansion

    We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.

  7. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  8. Sources

    Here are the sources that were queried against in your search that you can investigate further.

  9. Categories

    Here are the categories present within RRID that you can filter your data on

  10. Subcategories

    Here are the subcategories present within this category that you can filter your data on

  11. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.

X